Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.94
RTRX's Cash-to-Debt is ranked lower than
65% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.09 vs. RTRX: 0.94 )
Ranked among companies with meaningful Cash-to-Debt only.
RTRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13  Med: 1.51 Max: No Debt
Current: 0.94
Equity-to-Asset 0.59
RTRX's Equity-to-Asset is ranked lower than
57% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. RTRX: 0.59 )
Ranked among companies with meaningful Equity-to-Asset only.
RTRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.16  Med: 0.36 Max: 0.63
Current: 0.59
-3.16
0.63
Interest Coverage N/A
RTRX's Interest Coverage is ranked higher than
66% of the 635 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 105.95 vs. RTRX: N/A )
Ranked among companies with meaningful Interest Coverage only.
RTRX' s Interest Coverage Range Over the Past 10 Years
Min: 175.78  Med: 9999.5 Max: No Debt
Current: N/A
Beneish M-Score: -2.47
WACC vs ROIC
9.19%
-21.67%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -61.16
RTRX's Operating Margin % is ranked lower than
83% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.42 vs. RTRX: -61.16 )
Ranked among companies with meaningful Operating Margin % only.
RTRX' s Operating Margin % Range Over the Past 10 Years
Min: -61.16  Med: 197.3 Max: 2105.03
Current: -61.16
-61.16
2105.03
Net Margin % -55.85
RTRX's Net Margin % is ranked lower than
83% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.16 vs. RTRX: -55.85 )
Ranked among companies with meaningful Net Margin % only.
RTRX' s Net Margin % Range Over the Past 10 Years
Min: -55.85  Med: 199.98 Max: 2059.37
Current: -55.85
-55.85
2059.37
ROE % -22.65
RTRX's ROE % is ranked lower than
78% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. RTRX: -22.65 )
Ranked among companies with meaningful ROE % only.
RTRX' s ROE % Range Over the Past 10 Years
Min: -22.65  Med: 36.75 Max: 89.25
Current: -22.65
-22.65
89.25
ROA % -13.45
RTRX's ROA % is ranked lower than
77% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. RTRX: -13.45 )
Ranked among companies with meaningful ROA % only.
RTRX' s ROA % Range Over the Past 10 Years
Min: -575  Med: -240.01 Max: 36.2
Current: -13.45
-575
36.2
3-Year EBITDA Growth Rate -23.50
RTRX's 3-Year EBITDA Growth Rate is ranked lower than
89% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. RTRX: -23.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RTRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -23.5
Current: -23.5
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RTRX's 30-Y Financials

Financials (Next Earnings Date: 2017-06-01 Est.)


Revenue & Net Income
Equity & Asset
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

RTRX Guru Trades in Q2 2016

Steven Cohen 174,800 sh (New)
Paul Tudor Jones 37,967 sh (+57.12%)
Jim Simons Sold Out
» More
Q3 2016

RTRX Guru Trades in Q3 2016

Lee Ainslie 148,661 sh (New)
Paul Tudor Jones 66,213 sh (+74.40%)
Steven Cohen 150,800 sh (-13.73%)
» More
Q4 2016

RTRX Guru Trades in Q4 2016

John Paulson 55,000 sh (New)
Jim Simons 41,300 sh (New)
Steven Cohen 412,735 sh (+173.70%)
Lee Ainslie Sold Out
Paul Tudor Jones 51,666 sh (-21.97%)
» More
Q1 2017

RTRX Guru Trades in Q1 2017

Jim Simons 364,800 sh (+783.29%)
Steven Cohen 964,800 sh (+133.76%)
Paul Tudor Jones 61,733 sh (+19.48%)
John Paulson Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with RTRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325411    SIC: 2834
Compare:OTCPK:ABSCF, AMEX:TXMD, NAS:RMTI, NAS:ZGNX, NAS:NBRV, OTCPK:VEGPF, NAS:ALIM, AMEX:NNVC, OTCPK:MAYNF, NAS:OASM, OTCPK:PXSLY, NAS:PRPH, NAS:TNXP, AMEX:AXN, NAS:IMNP, NAS:ALQA, NAS:NVGN, OTCPK:INNV, OTCPK:SUWN, AMEX:CPHI » details
Traded in other countries:17R.Germany,
Headquarter Location:USA
Retrophin Inc is a fully integrated biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases.

Retrophin Inc was incorporated as Desert Gateway, Inc. as an Oklahoma corporation on February 8, 2008. On February 14, 2013, the Company changed its name to Retrophin, Inc. The Company is a fully integrated biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It is developing Syntocinon Nasal Spray in the U.S. to assist initial postpartum milk ejection, which it refers to as aiding milk let-down, and for the treatment of Schizophrenia and Autism. It is also developing RE-034, a synthetic hormone analogue that is composed of the first 24 amino acids of the 39 amino acids contained in the naturally occurring adrenocorticotrophic hormone, or ACTH, for the treatment of Infantile Spasms, or IS, and Nephrotic Syndrome, or NS. It is developing sparsentan, formerly known as RE-021, a dual acting receptor antagonist of angiotensin and endothelin receptors, for the treatment of focal segmental glomerulosclerosis, or FSGS. The Company competes with Genentech, GlaxoSmithKline, Roche, Novartis, Pfizer, Boehringer Ingelheim, Sanofi, BioMarin, Sarepta, Vertex, and Jazz Pharmaceuticals. The Company is subject to federal, state and local laws governing the use, handling and disposal of these materials.

Top Ranked Articles about Retrophin Inc

Retrophin Announces Presentations for Late-Stage Clinical Development Programs at Upcoming Medical Congresses
Retrophin to Present at the Jefferies 2017 Global Healthcare Conference
Retrophin to Report First Quarter 2017 Financial Results
Retrophin Appoints Ron Squarer to Board of Directors
John A. Orwin Joins Retrophin Board of Directors

SAN DIEGO, March 23, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of John A. Orwin to the Company’s Board of Directors, effective immediately. Mr. Orwin currently serves as chief executive officer of Relypsa, Inc., a biopharmaceutical company focused on developing treatments for patients with conditions that are often overlooked and undertreated.
“John’s operational and commercial expertise strengthens our Board and will be invaluable to Retrophin as we advance our late-stage pipeline towards commercialization while maximizing the potential of our approved therapies,” said Stephen Aselage, chief executive officer of Retrophin. “We are very pleased John is joining us at this exciting time and look forward to his leadership.” Mr. Orwin is a biopharmaceutical industry veteran with more than 25 years of experience. He has served as chief executive officer of Relypsa since 2013. Previously, Mr. Orwin was chief executive officer and a director of Affymax. Before joining Affymax, Mr. Orwin held leadership positions in marketing, sales, and operations at Genentech, Johnson and Johnson, Alza Pharmaceuticals, Sangstat Medical Corporation, Rhone-Poulenc Rorer, and Schering-Plough. Mr. Orwin currently serves as a director of Seattle Genetics and Array BioPharma. Mr. Orwin earned a bachelor’s degree from Rutgers University and master’s degree in business administration from New York University. About Retrophin Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring late-stage candidates targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products, Thiola®, Cholbam®, and Chenodal®. Retrophin.com Forward-Looking Statements This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Without limiting the foregoing, these statements are often identified by the words "may", "might", "believes", "thinks", "anticipates", "plans", "expects", "intends" or similar expressions. In addition, expressions of our strategies, intentions or plans are also forward-looking statements. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, success of its commercial products as well as risks and uncertainties associated with the Company's pre-clinical and clinical stage pipeline. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties as included in the Company's most recent 10-K and other filings with the Securities and Exchange Commission.
Contact:

Chris Cline, CFA
Senior Director, Investor Relations
646-564-3680
[email protected]

Read more...
Retrophin to Present at the Barclays Global Healthcare Conference

SAN DIEGO, March 07, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Barclays Global Healthcare Conference in Miami on Wednesday, March 15, 2017 at 2:05 p.m. ET.
A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and an archived replay will be accessible for at least 30 days. About Retrophin Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Thiola®, Cholbam® and Chenodal®. Retrophin.com
Contact:
Chris Cline, CFA
Senior Director, Investor Relations
646-564-3680            
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 2.09
RTRX's PB Ratio is ranked higher than
62% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.03 vs. RTRX: 2.09 )
Ranked among companies with meaningful PB Ratio only.
RTRX' s PB Ratio Range Over the Past 10 Years
Min: 1.43  Med: 2.4 Max: 8.33
Current: 2.09
1.43
8.33
PS Ratio 5.17
RTRX's PS Ratio is ranked lower than
68% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. RTRX: 5.17 )
Ranked among companies with meaningful PS Ratio only.
RTRX' s PS Ratio Range Over the Past 10 Years
Min: 1.89  Med: 20.21 Max: 76.25
Current: 5.17
1.89
76.25
Price-to-Operating-Cash-Flow 1834.46
RTRX's Price-to-Operating-Cash-Flow is ranked lower than
99.99% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.62 vs. RTRX: 1834.46 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
RTRX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 149.05  Med: 284 Max: 2334.44
Current: 1834.46
149.05
2334.44
EV-to-EBIT -8.23
RTRX's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.99 vs. RTRX: -8.23 )
Ranked among companies with meaningful EV-to-EBIT only.
RTRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -24.3  Med: -3.75 Max: 12.6
Current: -8.23
-24.3
12.6
EV-to-EBITDA -10.49
RTRX's EV-to-EBITDA is ranked lower than
99.99% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.26 vs. RTRX: -10.49 )
Ranked among companies with meaningful EV-to-EBITDA only.
RTRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -29.8  Med: -3.75 Max: 11.2
Current: -10.49
-29.8
11.2

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -27.20
RTRX's 3-Year Average Share Buyback Ratio is ranked lower than
86% of the 442 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. RTRX: -27.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RTRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -592.1  Med: -524.4 Max: -27.2
Current: -27.2
-592.1
-27.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 5.29
RTRX's Price-to-Tangible-Book is ranked lower than
65% of the 705 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.61 vs. RTRX: 5.29 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RTRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.16  Med: 5.43 Max: 6.84
Current: 5.29
3.16
6.84
Price-to-Intrinsic-Value-Projected-FCF 8.05
RTRX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
76% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. RTRX: 8.05 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
RTRX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 6.45 Max: 8.39
Current: 8.05
0
8.39
Price-to-Median-PS-Value 0.26
RTRX's Price-to-Median-PS-Value is ranked higher than
97% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. RTRX: 0.26 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RTRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0.3 Max: 1.06
Current: 0.26
0
1.06
Earnings Yield (Greenblatt) % -12.15
RTRX's Earnings Yield (Greenblatt) % is ranked lower than
82% of the 1046 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.36 vs. RTRX: -12.15 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RTRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -12.2  Med: 16.85 Max: 22.6
Current: -12.15
-12.2
22.6

More Statistics

Revenue (TTM) (Mil) $125.7
EPS (TTM) $ -1.91
Beta1.25
Short Percentage of Float17.83%
52-Week Range $15.88 - 24.57
Shares Outstanding (Mil)38.17
» More Articles for RTRX

Headlines

Articles On GuruFocus.com
Retrophin Announces Presentations for Late-Stage Clinical Development Programs at Upcoming Medical C May 25 2017 
Retrophin to Present at the Jefferies 2017 Global Healthcare Conference May 23 2017 
Retrophin to Report First Quarter 2017 Financial Results Apr 20 2017 
Retrophin Appoints Ron Squarer to Board of Directors Apr 12 2017 
John A. Orwin Joins Retrophin Board of Directors Mar 23 2017 
Retrophin to Present at the Barclays Global Healthcare Conference Mar 07 2017 
Biotech Stocks to Watch After Senate Drug Report Dec 27 2016 
Retrophin At All-Time High Levels on RE-024 FDA-Status; Syneron Settles Legal Battle Jun 05 2015 
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Retrophin, Inc. Nov 28 2014 
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Retrophin, Inc. Oct 24 2014 

More From Other Websites
Edited Transcript of RTRX earnings conference call or presentation 4-May-17 8:30pm GMT May 26 2017
Retrophin Announces Presentations for Late-Stage Clinical Development Programs at Upcoming Medical... May 25 2017
Blog Coverage Merck's KEYTRUDA Becomes First Cancer Drug to be Approved by FDA Based on a Common... May 25 2017
Retrophin to Present at the Jefferies 2017 Global Healthcare Conference May 23 2017
ETFs with exposure to Retrophin, Inc. : May 12, 2017 May 12 2017
Retrophin, Inc. :RTRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 May 10 2017
Retrophin reports 1Q loss May 04 2017
Retrophin Reports First Quarter 2017 Financial Results May 04 2017
Retrophin, Inc. – Value Analysis (NASDAQ:RTRX) : April 27, 2017 Apr 27 2017
Pharma bro Martin Shkreli asks judge to order document hand-over, bar other evidence Apr 26 2017
Retrophin, Inc. breached its 50 day moving average in a Bullish Manner : RTRX-US : April 26, 2017 Apr 26 2017
Retrophin to Report First Quarter 2017 Financial Results Apr 20 2017
Ex-drug executive Shkreli wins separate fraud trial Apr 19 2017
Retrophin Appoints Ron Squarer to Board of Directors Apr 12 2017
Bristol-Myers' (BMY) sBLA For Opdivo Accepted by the FDA Apr 06 2017
Celgene (CELG) Gets Paragraph IV Notice Letter for Pomalyst Apr 05 2017
Bristol-Myers Announces Data on Immuno-oncology Drug Opdivo Apr 04 2017
Roche's Rituxan Gets FDA Advisory Committee's Recommendation Mar 30 2017
Bill Ackman Apologizes for Valeant Investment Error Mar 30 2017
Acorda Presents Data for Parkinson's Candidate CVT-301 Mar 30 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)